Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia

Hematology (United Kingdom)

Volumn 20, Issue 9, 2015, Pages 543-552

  Bârsan, Liliana ^a   Stanciu, Ana ^a   Stancu, Simona ^a   Căpuşă, Cristina ^a   Brătescu, Lavinia ^b   Mandache, Eugen ^a   Radu, Eugen ^a   Mircescu, Gabriel ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Sf Pantelimon Hemodialysis Centre International Healthcare Systems   (Romania)

Author keywords

Bone marrow; Chronic kidney disease; Hepcidin ferroportin system; Iron distribution; Renal anemia

Indexed keywords

C REACTIVE PROTEIN; FERROPORTIN; HEPCIDIN; IRON; TRANSFERRIN; CATION TRANSPORT PROTEIN; FERRITIN; HEPCIDIN 25, HUMAN; METAL TRANSPORTING PROTEIN 1;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CELLULAR DISTRIBUTION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROBLAST; ERYTHROPOIESIS; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RENAL ANEMIA; BLOOD; BONE MARROW; CHRONIC KIDNEY FAILURE; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; IRON DEFICIENCY ANEMIA; KIDNEY; MACROPHAGE; METABOLISM; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS;

ADULT; AGED; ANEMIA, IRON-DEFICIENCY; BONE MARROW; CATION TRANSPORT PROTEINS; ERYTHROBLASTS; FEMALE; FERRITINS; GENE EXPRESSION REGULATION; HEPCIDINS; HUMANS; IRON; KIDNEY; MACROPHAGES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; ROC CURVE;

EID: 84943594082     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845415Y.0000000004     Document Type: Article

References (32)

1. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–23.
2. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116(23):4754–61.
3. Ganz T. Hepcidin and iron regulation, 10 Years Later. Blood 2011;117(17):4425–33.
4. Gokal R, Millard PR, Weatherall DJ, Callender STE, Ledingham JGG, Oliver DO. Iron metabolism in haemodialysis patients: a study of the management of iron therapy and overload. QJM 1979;48(191):369–91.
5. Ali M, Fayemi AO, Rigolosi R, Frascino J, Marsden T, Malcolm D. Hemosiderosis in hemodialysis patients: an autopsy study of 50 cases. JAMA 1980;244(4):343–5.
6. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009;39(10):883–90.
7. Nakanishi T, Kuragano T, Nanami M, Otaki Y, Nonoguchi H, Hasuike Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol. 2010;32(5):439–46.
8. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis. 1995;26(2):292–9.
9. Gotloib L, Silverberg D, Shostak A. Iron deficiency is a very common cause of anemia in chronic kidney insufficiency and can often be corrected with IV iron. J Nephrol. 2006;19(2):161–7.
10. Stancu S, Stanciu A, Zugravu A, Bârsan L, Dumitru D, Lipan M et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non–dialysis-dependent CKD. Am J Kidney Dis. 2010;55(4):639–47.
11. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306(5704):2090–3.
12. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009; 75(9):976–81.
13. Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant. 2010;25(3):848–53.
14. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, et al. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol. 2010;5(6): 1010–4.
15. Malyszko J, Malyszko JS, Mysliwiec M. Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy. Kidney Blood Press Res. 2009;32(4):235–8.
16. Brătescu LO, Bârsan L, Munteanu D, Stancu S, Mircescu G. Is hepcidin-25 a clinically relevant parameter for the haemodialysis patients’ iron status? J Ren Nutr. 2010;20(Suppl. 5):S77–83.
17. Theurl I, Theurl M, Seifert M, Mair S, Nairz M, Rumpold H, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 2008;111(4):2392–9.
18. Liu XB, Nguyen NB, Marquess KD, Yang F, Haile DJ. Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages. Blood Cells Mol Dis. 2005; 35(1):47–56.
19. Nguyen NB, Callaghan KD, Ghio AJ, Haile DJ, Yang F. Hepcidin expression and iron transport in alveolar macrophages. Am J Physiol Lung Cell Mol Physiol. 2006;291(3):L417–25.
20. Zang DL, Senecal T, Ghosh MC, Olivierre-Willson H, Tu T, Roualt TA. Hepcidin regulates ferroportin expression and intracellular iron homeostasis by erythroblasts. Blood 2011;118(10): 2868–77.
21. Beaumont C. Can erythroblasts donate iron? Blood 2011; 118(10):2649–51.
22. Abcam#ab75883, Abcam#ab14007, Abcam#ab56297- Product specifications of Abcam, Cambridge, MA, available at http://www.abcam.com.
23. Abnova#H00030061-B01P - Product specification, Novus Biologicals, Littleton, CO, available at http://www.novusbio.com/PDFs/H00030061-B01P.pdf.
24. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009;113(21):5277–86.
25. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271–6.
26. Costa E, Swinkels DW, Laarakkers CM, Rocha-Pereira P, Rocha S, Reis F, et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol. 2009;122(4):226–9.
27. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using Protein Chip System. Blood 2006;108(4):1381–7.
28. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010;95(3):505–8.
29. Van der Putten K, Jie KE, Van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure. Eur J Heart Fail. 2010;12(9):943–50.
30. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65(3):1091–8.
31. Kroot JJC, Kemna EHJM, Bansal SS, Busbridge M, Campostrini N, Girelli D, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009; 94(12):1748–52.
32. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011;117(25):e218–25.